Olaparib is recommended, within its marketing authorisation, as an option for maintenance treatment of BRCA mutation-positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is only recommended if the company provides it according to the commercial arrangement.
Why the committee made these recommendations
This evaluation reviews the evidence for olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy (NICE technology appraisal guidance 598). It also reviews new evidence collected as part of the managed access agreement. The new evidence includes data from clinical trials and from people having treatment in the NHS in England.
The new clinical evidence shows that people having olaparib live longer and have more time before their cancer gets worse compared with people having placebo.
The most likely cost-effectiveness estimate for olaparib is within the range that NICE considers an acceptable use of NHS resources. So, it is recommended for routine use.